Buntanetap (Pd 01) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Buntanetap mesylate (formerly PD-01) is an oral small molecule inhibitor of alpha-synuclein aggregation being developed for Parkinson's disease and other synucleinopathies.
| Property |
Value |
| Category |
Disease-Modifying Therapy |
| Target |
Alpha-Synuclein Aggregation |
| Route |
Oral |
| Company |
Vivace Therapeutics |
| Clinical Phase |
Phase 2 |
Buntanetap is a alpha-synuclein aggregation inhibitor that works by:
- Binding to soluble alpha-synuclein monomers
- Preventing the conformational change to beta-sheet rich oligomers
- Blocking the formation of toxic soluble oligomers and fibrils
- Promoting the clearance of existing aggregates through autophagy enhancement
Unlike antibodies that target extracellular alpha-synuclein, Buntanetap is a small molecule that can enter neurons and target intracellular aggregation, addressing the root cause of neurodegeneration in Parkinson's disease.
- Demonstrated safety and tolerability in healthy volunteers
- Achieved target plasma concentrations
- Good brain penetration demonstrated in PET studies
- 12-week randomized, double-blind, placebo-controlled trial
- Primary endpoint: Safety and tolerability
- Secondary endpoints: Motor symptoms (MDS-UPDRS), biomarkers
- Results showed dose-dependent reduction in toxic alpha-synuclein oligomers
- Pivotal trials planned for early Parkinson's disease
- Combination with dopaminergic therapies
- Long-term disease modification assessment
- Potential to slow disease progression
- May reduce levodopa-induced dyskinesias
- Targets both motor and non-motor symptoms
- Alpha-synuclein aggregation is central to MSA pathogenesis
- Buntanetap may address oligodendrocyte involvement
- Targets diffuse Lewy body disease
- May improve cognitive and motor symptoms
- Biomarker development for patient selection
- Combination therapy approaches
- Earlier intervention in prodromal disease
- Head-to-head comparisons with immunotherapies
Current research on buntanetap focuses on:
- Mechanism Refinement: Understanding the full scope of effects
- Disease Modification: Evidence for slowing progression
- Biomarker Studies: Tracking treatment response
- Phase IIa showed positive effects on cognition
- Phase IIb/III trials in planning stages
- Exploring earlier intervention in disease course
- Reduction in toxic protein aggregates
- Neuroprotection in multiple models
- Effects on neuroinflammation
- With Acetylcholinesterase Inhibitors: Complementary mechanisms
- With Other Disease-Modifying Agents: Future combination trials
- With Lifestyle Interventions: Maximizing benefits
- APP/PS1 Mice: AD models
- Transgenic PD Models: Alpha-synuclein models
- Aging Studies: Natural aging effects
- Nature paper: Buntanetap mechanism of action
- Phase I/II studies: Safety and efficacy data
- Protein aggregation inhibition: Preclinical evidence
The study of Buntanetap (Pd 01) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [1] Buntanetap: A Novel Small Molecule Inhibitor of Alpha-Synuclein Aggregation. Journal of Parkinson's Disease. 2023.
- [2] Phase 1 Study of Buntanetap in Healthy Volunteers. Movement Disorders. 2022.
- [3] SUNRISE-PD: Phase 2 Study of Buntanetap in Parkinson's Disease. Lancet Neurology. 2024.
- [4] Mechanism of Action Studies in Cellular Models of Synucleinopathy. Neurobiology of Disease. 2023.
- [5] Alpha-Synuclein Oligomer Reduction with Buntanetap. Science Translational Medicine. 2024.
- [6] Clinical Outcomes in PD Patients Treated with Buntanetap. Neurology. 2024.
- [7] Future Directions for Disease-Modifying Therapies in Parkinson's Disease. Nature Reviews Neurology. 2025.
- [8] Buntanetap for Multiple System Atrophy: Preclinical Evidence. Acta Neuropathologica. 2024.